Table III.
Univariate analysis for RGS2 and clinical characteristics in The Cancer Genome Atlas cohort.
| Characteristic | HR | 95% CI | P-value |
|---|---|---|---|
| RGS2 expression (low vs. high) | 0.324 | 0.154–0.683 | 0.003 |
| Age (≥60 vs. <60 years) | 2.014 | 1.213–3.342 | 0.007 |
| ER status (positive vs. negative) | 1.017 | 0.567–1.825 | 0.954 |
| PR status (positive vs. negative) | 0.799 | 0.477–1.338 | 0.393 |
| HER-2 status (positive vs. negative vs. uncertain) | 0.517 | 0.207–1.295 | 0.159 |
| Distant metastasis (presence vs. absence) | 3.642 | 1.770–7.495 | <0.001 |
| Tumor size (>2 vs. ≤2 cm) | 1.736 | 0.876–3.439 | 0.114 |
| Lymph node metastasis (presence vs. absence) | 1.676 | 0.970–2.894 | 0.064 |
| Stage (III–IV vs. I–II) | 2.277 | 1.363–3.803 | 0.002 |
HR, hazard ratio; 95% CI, 95% confidence interval; RGS2, regulator of G protein signaling 2; ER, estrogen receptor; PR, progesterone receptor; HER-2, human epidermal growth factor receptor 2.